SCHEMBL25520103

SCHEMBL25520103

CC(C)NC(=O)NC1CCC(c2ncc(Br)[nH]2)CC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 5/20 0.48
MAPK9 P45984 5/20 0.48
MAPK10 P53779 5/20 0.48
KDM5A P29375 2/20 0.39
EPHX1 P07099 3/20 0.38
LMNA P02545 1/20 0.38
CYP11B2 P19099 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
JAK3 P52333 1/20 0.36
TTK P33981 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SMYD3 Q9H7B4 1/20 0.34
KDM5C P41229 1/20 0.33
KDM5B Q9UGL1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28913117 0.77 JAK1 (0.48) JAK2JAK1JAK3
SCHEMBL25519927 0.77 JAK1 (0.48) JAK2JAK1JAK3
SCHEMBL15262638 0.72 EPHX1 (0.58) EPHX1LMNAALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL2625568 0.72 EPHX1 (0.58) EPHX1LMNAALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL17810262 0.71 HPGDS (0.33) ALDH1A1
SCHEMBL2625559 0.67 EPHX1 (0.61) EPHX1LMNAALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL2625555 0.67 EPHX1 (0.67) EPHX1LMNAALDH1A1SMN1; SMN2
SCHEMBL23573335 0.66 ALDH1A1 (0.56) EPHX1LMNAALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL14654896 0.66 EPHX1 (0.66) EPHX1LMNAALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL12521938 0.66 EPHX2 (0.65) EPHX1LMNAALDH1A1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2023-05-11 US disclosed
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND RAD51, FANCI, BLM MAPK8 1369/4885MAPK9 910/4885MAPK10 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.